Filing Flows › Comparisons › BTCY vs NXGL
Biotricity vs Nexgel: BTCY and NXGL compared
Biotricity is the larger company: $4.3M of revenue in its latest quarter (Q1 FY27) against $3.7M for Nexgel (Q2 2026). Nexgel is growing faster (+28% against +10% a year earlier). Biotricity is more profitable, with an operating margin of 3.7% against -68.0%.
Where the money goes: BTCY and NXGL
Biotricity (BTCY) · Q1 FY27
Biotricity, Q1 FY27: revenue $4.3M (+10% year over year), operating margin 3.7%, net loss $959K, operating cash flow $507K. The chart follows the revenue to costs, profit and cash.
Nexgel (NXGL) · Q2 2026
Nexgel, Q2 2026: revenue $3.7M (+28% year over year), operating margin -68.0%, net loss $3.6M, operating cash flow −$2.2M. The chart follows the revenue to costs, profit and cash.
| Biotricity (BTCY) | Nexgel (NXGL) | |
|---|---|---|
| Latest quarter | Q1 FY27 | Q2 2026 |
| Revenue | $4.3M | $3.7M |
| Revenue growth, Y/Y | +10% | +28% |
| Operating margin | 3.7% | -68.0% |
| Net earnings | −$959K | −$3.6M |
| Net margin | -22.4% | -97.8% |
| Operating cash flow | $507K | −$2.2M |
Where the revenue comes from
Biotricity
- Technology Fees: $4.2M (97%)
- Device Sales: $111K (3%)
Questions
Which is bigger, Biotricity or Nexgel?
Biotricity is the larger company: $4.3M of revenue in its latest quarter (Q1 FY27) against $3.7M for Nexgel (Q2 2026).
Is Biotricity or Nexgel growing faster?
Nexgel is growing faster (+28% against +10% a year earlier).
Which is more profitable, Biotricity or Nexgel?
Biotricity is more profitable, with an operating margin of 3.7% against -68.0%.
More: Biotricity earnings · how Biotricity makes money · Nexgel earnings · how Nexgel makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 19, 2026; 10-Q filed Aug 17, 2026). Fiscal quarters can end on different dates. Not investment advice.